AVDL
Avadel Pharmaceuticals plc
$16.00
-$0.20(-1.23%)
66
Overall
--
Value
66
Tech
--
Quality
Market Cap
$1.50B
Volume
1.19M
52W Range
$6.38 - $16.66
Target Price
$20.20
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $173.0M | $150.2M | $173.2M | $103.3M | $59.2M | $22.3M | $110.0K | $116.0K | $28.0M | $169.1M | ||
| Total Revenue | $173.0M | $150.2M | $173.2M | $103.3M | $59.2M | $22.3M | $110.0K | $116.0K | $28.0M | $169.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-11.4M | $-13.2M | $-16.3M | $-17.5M | $12.1M | $5.7M | $53.0K | -- | $846.0K | $15.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $161.6M | $137.0M | $154.4M | $84.7M | $47.1M | $16.6M | $57.0K | $116.0K | $27.1M | $153.8M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $59.9M | $92.7M | $95.9M | $146.3M | $64.8M | $56.6M | $85.6M | $95.2M | $165.0M | $196.2M | ||
| Research & Development | $25.6M | $34.6M | $33.4M | $39.3M | $32.9M | $20.4M | $17.1M | $20.7M | $13.3M | $15.2M | ||
| Research Expense | $25.6M | $34.6M | $33.4M | $39.3M | $32.9M | $20.4M | $17.1M | $20.7M | $13.3M | $15.2M | ||
| Selling, General & Administrative | $21.7M | $44.2M | $58.9M | $100.4M | $30.2M | $32.4M | $68.5M | $74.5M | $151.7M | $181.0M | ||
| Selling & Marketing Expenses | $21.7M | $44.2M | $58.9M | $100.4M | -- | -- | -- | -- | $6.5M | $12.2M | ||
| General & Administrative Expenses | $-752.0K | $-970.0K | $-1.1M | $-1.2M | $30.2M | $32.4M | $68.5M | $74.5M | $151.7M | $181.0M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | -- | -- | -- | $6.5M | $12.2M | ||
| Salaries & Wages | $-7.7M | $-14.7M | $-8.1M | $-7.9M | -- | -- | -- | $7.0M | $15.8M | $20.4M | ||
| Depreciation & Amortization | $12.6M | $13.9M | $3.7M | $6.6M | $816.0K | $406.0K | $97.0K | $162.0K | $254.0K | $132.0K | ||
| Depreciation & Amortization | $12.6M | $13.9M | $3.7M | $6.6M | $816.0K | $406.0K | $97.0K | $162.0K | $254.0K | $132.0K | ||
| Amortization | $12.6M | $13.9M | $3.7M | $6.6M | $816.0K | $406.0K | $18.1M | $22.9M | $16.8M | $16.8M | ||
| Other Operating Expenses | $-448.0K | $-1.6M | $-2.3M | $-1.1M | -- | $1.1M | $821.0K | $1.0M | $165.0M | $196.2M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $101.7M | $44.3M | $58.5M | $-61.6M | $-24.1M | $5.8M | $-85.5M | $-98.6M | $-137.8M | $-42.4M | ||
| EBITDA | $95.7M | $5.7M | $98.6M | $-90.3M | $-17.6M | $9.6M | $-82.4M | $-91.6M | $-149.1M | $-35.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $4.9M | $963.0K | $1.1M | $10.6M | $12.5M | $13.0M | $9.9M | $12.3M | $9.9M | $10.8M | ||
| Net Non-Operating Interest Income/Expense | $-3.6M | $672.0K | $1.1M | $-10.2M | $-12.5M | $-13.0M | $-9.9M | $-12.3M | $-9.9M | $-10.8M | ||
| Gain on Sale of Securities | $677 | $1.3M | $1.7M | $956.0K | $1.1M | $-832.0K | $2.3M | $-536.0K | $87.0K | $4.2M | ||
| Other Income/Expense | $31.0M | $55.8M | $-33.1M | $-24.6M | $2.0M | $-47.9M | $-2.3M | $-3.9M | $13.0M | $-4.2M | ||
| Other Special Charges | -- | $-6.5M | $2.1M | $1.9M | $-378.0K | $2.9M | $217.0K | $203.0K | $-13.1M | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-31.0M | $42.3M | $-3.3M | $-1.2M | $-169.0K | -- | -- | $3.3M | -- | -- | ||
| Special Income Charges | $31.0M | $-42.3M | $3.3M | $-66.1M | $169.0K | -- | -- | $-3.3M | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $66.1M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $82.6M | $-8.8M | $93.7M | $-102.6M | $-26.1M | $7.9M | $-83.2M | $-99.1M | $-150.9M | $-38.2M | ||
| Pre-Tax Income | $77.7M | $-9.7M | $92.7M | $-113.2M | $-38.6M | $-5.1M | $-93.1M | $-111.4M | $-160.8M | $-49.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $35.9M | $31.6M | $24.4M | $-17.9M | $-5.4M | $-12.1M | $-15.8M | $26.0M | $-501.0K | $-247.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $41.8M | $-41.3M | $68.3M | $-95.3M | $-33.2M | $7.0M | $-77.3M | $-137.5M | $-160.3M | $-48.8M | ||
| Net Income (Continuing Operations) | $41.8M | $-41.3M | $68.3M | $-95.3M | $-33.2M | $7.0M | $-77.3M | $-137.5M | $-160.3M | $-48.8M | ||
| Net Income (Discontinued Operations) | $41.8M | $-41.3M | $68.3M | $-95.3M | $-33.2M | $7.0M | $-77.3M | $-137.5M | $-160.3M | $-48.8M | ||
| Net Income (Common Stockholders) | $41.8M | $-41.3M | $68.3M | $-95.3M | $-20.3M | $7.0M | $-77.3M | $-137.5M | $-160.3M | $-48.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-49.3M | ||
| TOTALS | ||||||||||||
| Total Expenses | $48.5M | $79.4M | $79.6M | $128.8M | $76.9M | $62.3M | $85.7M | $95.2M | $165.8M | $211.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $40.6M | $41.2M | $40.5M | $37.3M | $37.4M | $53.0M | $58.5M | $60.1M | $80.2M | $95.1M | ||
| Average Shares Outstanding (Diluted) | $43.6M | $41.2M | $41.8M | $37.3M | $37.4M | $54.9M | $58.5M | $60.1M | $80.2M | $95.1M | ||
| Shares Outstanding | $40.2M | $41.4M | $38.0M | $37.4M | $46.4M | $58.5M | $59.0M | $64.5M | $90.6M | $97.1M | ||
| Basic EPS | $1.03 | $-1 | $1.69 | $-2.55 | $-0.89 | $0.13 | $-1.32 | $-2.29 | $-2 | $-0.51 | ||
| Basic EPS (Continuing Operations) | $1.03 | $-1 | -- | -- | $-0.89 | $0.13 | $-1.32 | $-2.29 | $-2 | $-0.51 | ||
| Diluted EPS | $0.96 | $-1 | $1.63 | $-2.55 | $-0.89 | $0.13 | $-1.32 | $-2.29 | $-2 | $-0.51 | ||
| Diluted EPS (Continuing Operations) | $0.96 | $-1 | -- | -- | $-0.89 | $0.13 | $-1.32 | $-2.29 | $-2 | $-0.51 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D | $172.5M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Acquisition Expense | -- | -- | -- | -- | $845.0K | $3.3M | -- | -- | -- | -- | ||
| Earnings from equity interest | $721.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $721.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | $-2.7M | $45.8M | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | -- | $14.9M | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | $14.9M | -- | -- | -- | -- | ||
| Other Gand A | $-752.0K | $-970.0K | $-1.1M | $-1.2M | $30.2M | $32.4M | $68.5M | $74.5M | $151.7M | $181.0M | ||
| Other Impairment Of Capital Assets | $-12.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-752.0K | $-970.0K | $-1.1M | $-1.2M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $21.7M | $44.2M | $58.9M | $100.4M | -- | -- | -- | -- | -- | -- | ||
| Restruct | $-31.0M | $42.3M | $-3.3M | $-1.2M | $-169.0K | -- | -- | $3.3M | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVDL | $16.00 | -1.2% | 1.19M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Avadel Pharmaceuticals plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW